| IPSEN S.A. PORT. EO 1 |
| Frankreich |
| Gesundheit |
| FR0010259150 / A0ESMG |
| I7G (Frankfurt) |
| FRA:I7G, ETR:I7G, I7G:GR |
| - |
| https://www.ipsen.com/ |
|
Ipsen S.A. is a French biopharmaceutical company headquartered in Paris, specializing in the development and commercialization of transformative medicines across three core therapeutic areas: oncology..
>Volltext.. |
| 12385.1 Mio. EUR |
| 11830.47 Mio. EUR |
| 3730.82 Mio. EUR |
| 1645.83 Mio. EUR |
| 450.13 Mio. EUR |
| 5.44 EUR |
| 985 Mio. EUR |
| 1548.29 Mio. EUR |
| 1155.41 Mio. EUR |
| 1.06 |
| 8.1% |
| 28.22% |
| 1.4 EUR |
| 0.94% |
| 0.94% |
| 04.06.25 - 1.4€ 30.05.24 - 1.2€ >weitere anzeigen... |
| - |
| IPSEN |
| 23.03.26 |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|